Abstract Details

Title Distinguishing Parkinsonian Dementia Syndromes from Alzheimer's Disease: Behavioral and Cognitive Characteristics Using SAGE

Topic Aging and Dementia

Presentation(s) P07 - (-)

Poster/Presentation
Number 134

Objective

Background BACKGROUND: DLB and PDD are the most common Parkinsonian dementia syndromes. While motor features typically distinguish these conditions from AD, there is limited data comparing cognitive and behavioral profiles.

Design/Methods DESIGN/METHODS: Subjects were recruited from Memory Disorders and Movement Disorders Clinics at Ohio State University. Twenty subjects with either DLB or PPD, based on standard clinical criteria, were closely matched by age, gender, education level and MMSE score to twenty subjects with AD. Cognitive and behavioral characteristics of the groups were compared by Wilcoxon signed rank test with their performance on Self-Administered Gerocognitive Examination (SAGE), Consortium to Establish a Registry for Alzheimer's Disease (CERAD), MMSE, verbal fluency (FAS), UPDRS, Activities of Daily Living Inventory (ADL), Neuropsychiatric Inventory (NPI), and Mayo Sleep Questionnaire (MSQ).

Results RESULTS: Forty Caucasian subjects were 26 male, 14 female. Subjects were ages 73.9±4.9 (DLB/PPD) and 74.9±4.9 (AD), MMSE 22.4±3.7 (DLB/PDD) and 22.6±4.4 (AD), education years 15.4±2.9 (DLB/PDD) and 14.6±2.2 (AD), and UPDRS III (motor) 26.1±4.9 (DLB/PDD) and 3.7±3.6 (AD). DLB and PPD subjects performed significantly better than AD subjects on orientation using SAGE and MMSE, in memory recognition discrimination, false positive error rate, and delayed word recall using CERAD (all p<0.05). DLB and PPD subjects performed significantly worse than AD subjects on executive function using SAGE, constructions using SAGE, FAS, and ADLs. DLB and PPD subjects had more hallucinations, orthostatic hypotension symptoms, impaired alertness, and sleep apnea. No significant differences were seen between the groups regarding learning curve, naming, or total scores of NPI, SAGE, or CERAD.

Conclusions CONCLUSIONS: Executive, visuospatial and orientation domains of SAGE distinguish DLB/PDD from AD subjects. We found a retrieval memory disturbance is characteristic for DLB and PPD subjects and an amnestic memory impairment for AD subjects.

Authors/Disclosures
Douglas W. Scharre, MD, FAAN (Ohio State University) PRESENTER	Dr. Scharre has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for BrainTest, Inc. Dr. Scharre has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Otsuka. Dr. Scharre has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai. Dr. Scharre has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Scharre has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Eisai. Dr. Scharre has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Eli Lilly. The institution of Dr. Scharre has received research support from InSightec. The institution of Dr. Scharre has received research support from Alzheimer's Therapeutic Research Institute (ATRI). The institution of Dr. Scharre has received research support from Eisai. The institution of Dr. Scharre has received research support from vTv Therapeutics. The institution of Dr. Scharre has received research support from National Institute of Health. The institution of Dr. Scharre has received research support from Eli Lilly. The institution of Dr. Scharre has received research support from Biogen. The institution of Dr. Scharre has received research support from Roche. The institution of Dr. Scharre has received research support from Percision Medicine. The institution of Dr. Scharre has received research support from Premier Research Group. The institution of Dr. Scharre has received research support from Genetch. The institution of Dr. Scharre has received research support from Avanir. The institution of Dr. Scharre has received research support from Cerevel Therapeutics. The institution of Dr. Scharre has received research support from Janssen. The institution of Dr. Scharre has received research support from Cassava. The institution of Dr. Scharre has received research support from UniQure. The institution of Dr. Scharre has received research support from Cognition Therapeutics. The institution of Dr. Scharre has received research support from Cognitive Research Corporation. The institution of Dr. Scharre has received research support from EIP. The institution of Dr. Scharre has received research support from Cognito. Dr. Scharre has received intellectual property interests from a discovery or technology relating to health care. Dr. Scharre has received intellectual property interests from a discovery or technology relating to health care.
Amiram Katz, MD (MedAhead, Inc.)	No disclosure on file
Shu-Ing Chang (The Ohio State University)	No disclosure on file
	No disclosure on file
Punit Agrawal, DO (The Ohio State University Wexner Medical Center - OSU P)	No disclosure on file
	No disclosure on file
Maria Kataki, MD, PhD, FAAN (Albany Medical College, Albany NY)	No disclosure on file
Shannon L. Linder (Ohio State University, Wexner Medical Center)	No disclosure on file
Ariane Park, MD, MPH (Wexner Medical Center At The Ohio State University)	An immediate family member of Dr. Park has stock in LucidHealth. The institution of Dr. Park has received research support from Parkinson Foundation. The institution of Dr. Park has received research support from National Institute of Neurological Disorders and Stroke. The institution of Dr. Park has received research support from Rho, Inc. The institution of Dr. Park has received research support from Cerevel Therapeutics. The institution of Dr. Park has received research support from Addex Therapeutics.

��ɫ��

��ɫ��